Prss56-Cre Nf1 Mouse Model for NF1 Pathology
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models for Neurofibromatosis type 1 do not accurately recapitulate the development of diffuse cutaneous neurofibromas, CNS tumors, leukemia, pseudarthrosis, and scoliosis, limiting their effectiveness in drug screening and understanding the disease.
Innovation Solution
A transgenic non-human animal model with specific inactivation of the Nf1 gene in Prss56-expressing cells and their derivatives, using the Cre-Lox recombination system to achieve biallelic deletion of the Nf1 gene in boundary cap cells and their progeny, which faithfully mimics the human disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional Nf1 mouse models (neuronal, melanocyte, or Schwann cell lineage conditional knockout) are used, then specific aspects of NF1 pathology can be studied, but they fail to recapitulate the full spectrum of human NF1 symptoms including diffuse cutaneous NFBs, CNS tumors, leukemia, pseudarthrosis, and scoliosis
Solution Approach 1:
The invention segments the Nf1 gene inactivation to specific cell lineages using Cre-Lox technology. The Prss56-Cre driver enables selective deletion of Nf1 in boundary cap cells and their derivatives (Schwann cells, melanocytes, endoneurial fibroblasts), while preserving Nf1 function in other cell types. This segmented approach allows comprehensive NF1 symptom recapitulation without requiring multiple separate transgenic lines, thus improving disease model accuracy while managing genetic complexity.
Solution Approach 2:
The Prss56-Cre driver line serves as a universal tool that enables simultaneous study of multiple NF1-related pathologies (cutaneous NFBs, plexiform NFBs, CNS tumors, leukemia, pseudarthrosis, scoliosis) within a single mouse model. This multi-functional approach replaces the need for multiple specialized models, improving both disease representation accuracy and experimental efficiency.
2Reliability
If Nf1 gene is inactivated in all cells (global knockout), then complete NF1 pathology develops, but homozygous Nf1â/â mice die during embryonic development
Solution Approach 1:
The invention applies local quality by restricting Nf1 inactivation to specific tissues (peripheral nervous system, skin, melanocytes) where NF1 pathology manifests, while maintaining Nf1 function in other tissues essential for embryonic survival. The Prss56-Cre driver ensures spatially selective gene deletion, allowing complete NF1 phenotype development in target tissues without embryonic lethality.
Solution Approach 2:
The global Nf1 knockout is segmented into tissue-specific deletions using the Prss56-Cre driver. This segmentation preserves Nf1 function in critical organs while inducing pathology in NF1-affected tissues, resolving the contradiction between complete disease phenotype and embryonic survival.
3Ease of manufacture
If surgical ablation is used to treat NFBs, then existing tumors are removed, but the injury triggers development of additional tumors and does not prevent recurrence
Solution Approach 1:
The mouse model enables self-service by allowing spontaneous development and progression of NFBs without surgical intervention. This eliminates the harmful effect of surgery-induced tumor formation while maintaining natural disease progression, enabling study of NF1 pathology and treatment testing in a more physiologically relevant context.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This model effectively develops cutaneous and plexiform neurofibromas, along with associated symptoms like splenomegaly, hamartomas, and cognitive dysfunctions, providing a more accurate representation of Neurofibromatosis type 1 for drug screening and research.
Implementation Method 1
using the Cre-Lox recombination system to achieve biallelic deletion of the Nf1 gene in boundary cap cells and their progeny
Data Source
AI summary
A transgenic non-human animal model for Neurofibromatosis type 1, wherein the Nf1 gene is specifically inactivated in BC cells and derivatives thereof. Also, an in vitro method of producing cutaneous and plexiform Neurofibromas (NFBs) and/or for studying the development and composition of plexiform NFBs, including culturing in vitro Prss56-expressing cells and-derivatives thereof obtained from the transgenic non-human animal model. Further, a method for screening a candidate compound for use as a drug to treat Neurofibromatosis type 1, cutaneous NFBs and/or plexiform NFBs including contacting the candidate compound Prss56-expressing cells and-derivatives thereof obtained from the transgenic non-human animal model or administering the candidate compound to the transgenic non-human animal model.